This week I am looking at Reckitt Benckiser, a British multinational consumer goods company. The company, known for brands such as Dettol, Nurofen and Durex, released its first quarter trading update on 20th April, quoting a 2 per cent like-for-like sales growth against the same period last year. Whilst the results appeared reasonable, they narrowly missed analyst expectations and the share price fell on the back of this.
Management has been enthusiastically engaging in M&A activity in an attempt to promote growth in the current economic environment. The purchase in February 2017 of Mead Johnson, an international baby formula manufacturer, continues to integrate well. There have been reported cost-saving synergies of $25m so far and an expectation of $300m over the next three years. Following the acquisition, 50% of group revenue now comes from higher margin consumer healthcare brands. In an attempt to streamline the business the company also restructured itself into two separate divisions in January: health and home hygiene. With health clearly the growth driver of the business, management are now reviewing the lower margin home hygiene division.
Furthermore, following a strategic review of its food businesses, Reckitt Benckiser finalised a deal in the summer to sell its “French’s Food” brands to McCormick & Company Inc. The deal was completed for a cash sum of $4.2 billion and received well by investors. The company stated the cash would be used to reduce debt from the aforementioned Mead Johnson acquisition and continue to consolidate the business into more defined divisions.
Despite the recent setbacks, management remain confident that the steps taken to focus the business will continue to drive long term growth. With its portfolio of power brands enabling the company to enjoy comparably high operating margins, it will be important to see whether this can be maintained under growing pressures from global competitors.